Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by Etest.
Clinafloxacin, levofloxacin, sparfloxacin and trovafloxacin were tested by Etest against 188 Streptococcus pneumoniae isolates. Clinafloxacin and trovafloxacin were 2-4-fold more potent than sparfloxacin and 8-fold more than levofloxacin. Two isolates, both serotype 6, with high-level quinolone resistance (> or = 8 micrograms/ml) were detected. The Etest is a practical means for determining S. pneumoniae susceptibilities to new fluoroquinolones.
Waites
K
K
Department of Pathology, University of Alabama at Birmingham 35233-7331, USA. waites@path.uab.edu
Brookings
E
E
Nix
S
S
Robinson
A
A
Gray
B
B
Swiatlo
E
E
D000890:Anti-Infective Agents / Q000494:pharmacology*; D024841:Fluoroquinolones; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests / Q000379:methods; D009287:Naphthyridines / Q000494:pharmacology; D015242:Ofloxacin / Q000494:pharmacology; D015363:Quinolones / Q000494:pharmacology; D013296:Streptococcus pneumoniae / Q000187:drug effects*
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D015363:Quinolones; D064704:Levofloxacin; C057477:clinafloxacin; C080163:trovafloxacin; D015242:Ofloxacin; C061363:sparfloxacin